Kenvue, Inc. (KVUE)

Over the past six months, Kenvue's stock experienced its most significant single-day decline since its IPO due to CEO remarks about challenges in selling seasonal products. Kenvue adjusted its fiscal year 2025 EPS guidance, forecasting flat growth, but revised net sales growth guidance upward. Kenvue reported its second-quarter 2025 earnings, surpassing EPS estimates but missing revenue expectations. Kenvue announced and paid a quarterly dividend of $0.2075 per share. The company's stock price has been negatively impacted by accusations regarding its Tylenol product potentially increasing autism when used during pregnancy, which Kenvue is refuting. Jeff Smith of Starboard expressed a positive outlook on Kenvue's valuation. Jefferies maintained a "Buy" recommendation, while Deutsche Bank adjusted its price target to a "Hold" rating. Kenvue is scheduled to announce its third-quarter 2025 financial results on November 6, 2025.

Demand for Kenvue's products exhibits seasonality, impacting its financial performance. Seasonal demand shifts, particularly for allergy medicine and sunscreen, affected Q2 results due to a longer winter delaying the onset of spring.

Kenvue, Inc. is an American consumer health company that was spun off from Johnson & Johnson in 2023 and operates within the consumer products sector, focusing on consumer health. Kenvue's business is segmented into Self Care, Skin Health and Beauty, and Essential Health, with brands including Aveeno, Band-Aid, Benadryl, Johnson's Baby, Listerine, Lactaid, Mylanta, Neutrogena, Tylenol, Visine, and Zyrtec, addressing a wide range of health and wellness needs.

Kenvue has a significant global presence, serving approximately one billion consumers across 165 countries. The company's operations span North America, Asia Pacific (APAC), Europe, the Middle East, Africa (EMEA), and Latin America (LATAM).

Kenvue's brand reputation has been affected by accusations that its Tylenol product increases autism risk when used during pregnancy, which the company refutes. This follows previous issues related to its talc-based baby powder products. Despite these challenges, Kenvue emphasizes its commitment to product innovation and sustainability, including efforts to reduce its environmental footprint. The company's iconic brands are science-backed and recommended by healthcare professionals globally.

Institutional investors and hedge funds hold a significant majority of Kenvue's stock, owning 97.64% of the company. Major institutional owners include Price T Rowe Associates, Massachusetts Financial Services, Vanguard Total Stock Market Index Fund Investor Shares, Vanguard 500 Index Fund Investor Shares, and Geode Capital Management. Voya Investment Management LLC also significantly increased its stake in Kenvue during the last quarter.